Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice

Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice

Glioblastoma (GBM) causes poor survival in patients even with aggressive treatment. Temozolomide (TMZ) is the standard chemotherapeutic choice for GBM treatment but resistance always ensues. Protein kinase CK2 (CK2) contributes to tumour development and proliferation in cancer, and it is overexpress...

Full description

Bibliographic Details
Main Authors: Laura Ferrer-Font, Lucia Villamañan, Nuria Arias-Ramos, Jordi Vilardell, Maria Plana, Maria Ruzzene, Lorenzo A. Pinna, Emilio Itarte, Carles Arús, Ana Paula Candiota
Format: Article
Language:English
Published: MDPI AG 2017-02-01
Series:Pharmaceuticals
Subjects:
Glioma
preclinical brain tumour
GBM therapeutic target
CK2 inhibitors
CX-4945
metronomic therapy
immune system
Online Access:http://www.mdpi.com/1424-8247/10/1/24

Internet

http://www.mdpi.com/1424-8247/10/1/24

Similar Items